Zevra Therapeutics Q2 revenue beats estimates

Zevra Therapeutics

12/08/2025 21:19

Overview

Zevra Q2 2025 net revenue rises to $25.9 mln, beating analyst expectations

Net income for Q2 2025 reaches $74.7 mln, surpassing analyst estimates

Co completed $150 mln PRV sale, strengthening financial position

Outlook

Zevra plans to expand MIPLYFFA benefits to more patients in Europe

Company believes it has sufficient resources for strategic priorities without capital markets

Result Drivers

MIPLYFFA REVENUE - Generated $21.5 mln in net revenue, driving overall revenue growth

PRV SALE - Completed sale for $150 mln, bolstering financial position

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$25.88 mln
$22.50 mln (7 Analysts)
Q2 Net Income
Beat
$74.71 mln
$61.10 mln (4 Analysts)
Q2 Income from Operations
Miss
-$71.04 mln
-$4.39 mln (5 Analysts)
Q2 Pretax Profit
Beat
$76.91 mln
$54.10 mln (5 Analysts)
Q2 Operating Expenses
$24.22 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Zevra Therapeutics Inc is $25.00, about 53.2% above its August 11 closing price of $11.70

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release: ID:nGNX6Hxckz

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)